An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses

Hum Vaccin. Jan-Feb 2011;7 Suppl:199-204. doi: 10.4161/hv.7.0.14595.


H5N1 avian influenza continues to be a potential pandemic threat. Several vaccine candidates based on potentially pandemic influenza strains and antiviral drugs have been tested in preclinical and clinical studies. The data obtained so far have shown some promise, but have also revealed some shortcomings with both of these approaches. We have identified and characterized an H5N1 neuraminidasespecific monoclonal antibody which specifically inhibits N1 neuraminidase activity of highly pathogenic avian influenza (HPAI) strains from clades 1 and 2. We have also shown the protective efficacy of this antibody in animal challenge models using homologous virus. Specific and effective inhibition of N1 NA could make this mAb a useful therapeutic tool in the treatment of human infection, in particular with oseltamivirand zanamivir-resistant strains of HPAI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Neutralizing / administration & dosage
  • Antibodies, Neutralizing / immunology*
  • Antibodies, Viral / administration & dosage
  • Antibodies, Viral / immunology*
  • Body Weight
  • Disease Models, Animal
  • Female
  • Influenza A Virus, H5N1 Subtype / immunology*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Neuraminidase / immunology*
  • Orthomyxoviridae Infections / prevention & control*
  • Rodent Diseases / prevention & control
  • Survival Analysis
  • Viral Proteins / immunology*


  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Viral Proteins
  • NA protein, influenza A virus
  • Neuraminidase